Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Semax vs Zilucoplan (Zilbrysq)
An educational, source-based comparison of Semax and Zilucoplan (Zilbrysq) — how each peptide works, what it's researched for, and what to know before going deeper.
A synthetic heptapeptide derived from ACTH(4-10). Research suggests it modulates BDNF and NGF expression, dopaminergic and serotonergic tone, and shows neuroprotective effects in ischemia models.
- BDNF/NGF upregulation
- Ischemic stroke recovery (clinical use in Russia)
- Attention and cognitive performance
- Anxiolytic-style effects
- • Approved as a medication in Russia; not FDA-approved in the US.
- • Most clinical literature is in Russian.
Macrocyclic peptide complement C5 inhibitor for generalized myasthenia gravis.
A synthetic 15-amino-acid macrocyclic peptide that binds complement component C5 and blocks its cleavage to C5a/C5b, preventing formation of the membrane attack complex at the neuromuscular junction. Self-administered subcutaneously.
- Generalized myasthenia gravis (anti-AChR antibody positive)
- • FDA-approved 2023.
- • Requires meningococcal vaccination — risk of serious meningococcal infection.
- • Injection-site reactions common.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Two cited studies; independent replication needed.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Semax | Semax in the treatment of ischemic stroke | Zhurnal Nevrologii i Psikhiatrii | 2018 | Reported improved neurological recovery scores in acute ischemic stroke. |
| Semax | Semax and its analogs in neuroprotection | Molecular Neurobiology | 2020 | Review of neurotrophic and antioxidant mechanisms. |
| Zilucoplan (Zilbrysq) | RAISE phase 3 trial of zilucoplan in gMG | Lancet Neurology | 2023 | Significant improvement in MG-ADL and QMG scores vs placebo at week 12. |
Side-effect & safety grid
- Approved as a medication in Russia; not FDA-approved in the US.
- Most clinical literature is in Russian.
- FDA-approved 2023.
- Requires meningococcal vaccination — risk of serious meningococcal infection.
- Injection-site reactions common.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Semax vs Zilucoplan (Zilbrysq) — Key differences
- Class: Semax is classified as Nootropic · Neuroprotection, while Zilucoplan (Zilbrysq) is Complement Inhibitor · Neuromuscular.
- Primary research focus: Semax — bdnf/ngf upregulation; Zilucoplan (Zilbrysq) — generalized myasthenia gravis (anti-achr antibody positive).
- Tag: Cognition vs FDA-Approved · Neuromuscular.